Pharm-Olam International, contract research organization for InSite Vision, has completed a Phase 3 clinical trial of BromSite, an anti-inflammatory designed to reduce swelling and pain after cataract surgery.
The study included 268 cataract surgery patients. BromSite was administered the day of surgery and twice a day for two weeks post-surgery. The trial, designed to determine the safety and efficacy of the treatment, showed promising results.
More Articles on Ophthalmology:
American Academy of Ophthalmology Cautionary Campaign Gains Public Awareness
Las Vegas New Eyes, Eye Care Associates Partner
OptiMedica Laser System Clinical Presentations to be Shown at ASCRS 2013
The study included 268 cataract surgery patients. BromSite was administered the day of surgery and twice a day for two weeks post-surgery. The trial, designed to determine the safety and efficacy of the treatment, showed promising results.
More Articles on Ophthalmology:
American Academy of Ophthalmology Cautionary Campaign Gains Public Awareness
Las Vegas New Eyes, Eye Care Associates Partner
OptiMedica Laser System Clinical Presentations to be Shown at ASCRS 2013